Thrombosis caused by active rapamycin stents
Aoudia-Mentfakh, R.; Raoux, F.; Collet, J.P.; Fléron, M.H.; Drobinski, G.; Metzger, J.P.; Le Feuvre, C.
Archives des Maladies du Coeur et des Vaisseaux 97(2): 165-167
2004
ISSN/ISBN: 0003-9683 PMID: 15032417 Document Number: 568299
We report the case history of a patient aged 68 years presenting with a recurrence of anterior myocardial infarction complicated by cardiogenic shock with a thrombosis of an active rapamycin stent 77 days following the angioplasty procedure. This was provoked by stopping platelet anti-aggregant treatment, a diabetic background and in the context of scheduled surgery for cancer recurrence. Recent data in the literature combined with our observations prompt the continuation of anti-aggregant bi therapy for at least 9 months after endoprosthesis insertion even if an active stent is used. In the case where surgery is envisaged, it is necessary to wait at least 6 months after the rapamycin stent revascularisation procedure. If an extra-cardiac procedure is envisaged during the angioplasty, it would be preferable to not use an active stent.